Program Speakers

Timothy Crombleholme, MD  
Director, Colorado Fetal Care Center  
at the Colorado Institute of Maternal and  
Fetal Health

Melissa Mancuso, MD, FACOG, FACMG  
Director, D. Gary Benfield, MD Fetal  
Treatment Center  
Akron Children’s Hospital

Jack Rychik, MD  
Director, Fetal Heart Program;  
Director, Single Ventricle  
Survivorship Program  
Associate Chief for Academic Affairs  
Attending Cardiologist  
Children’s Hospital of Philadelphia

Deborah Krakow, MD  
Departments of Human Genetics and  
Orthopedic Surgery, University of California,  
Los Angeles

Roger Hudgins, MD  
Director, Division of Neurosurgery  
Director, NeuroDevelopmental Science Center  
Akron Children’s Hospital

Phillip Smith, MD, PhD  
Clinical Director, Heart Center  
Division Director, Cardiovascular Surgery  
Akron Children’s Hospital

Jeff St. Clair  
Reporter/Producer WKSU  
Local Host of “Here and  
Now” and “Fresh Air”

Who Should Attend  
This conference is designed for obstetricians,  
pediatric specialists, perinatal nurses and caregiv-  
ers working with families with prenatally-diagnosed  
birth defects or patients who have undergone fetal  
treatment.

Continuing Education  
Children’s Hospital Medical Center of Akron is  
accredited by the Ohio State Medical Association to  
provide continuing medical education for physicians.  
Children’s Hospital Medical Center of Akron  
designates this live educational activity for a  
maximum of 7.0 AMA PRA Category 1 Credits™.  
Physicians should only claim credit commensurate  
with the extent of their participation in the activity.

Disclosure Statement  
As a provider of the Ohio State Medical  
Association, it is the policy to require the disclosure  
of the existence of any financial interest a planning  
committee member and presenters have with either  
the commercial supporter(s) of this activity or the  
manufacture(s) of any commercial product(s)  
discussed, and when necessary, resolve any  
potential conflict. None of the planning committee  
members or presenters has a financial conflict to  
disclosure or resolve.

Registration  
Registration deadline is Sept. 5, 2014.

Planning Committee  
Melissa Mancuso, MD  
Haynes B. Robinson, MD  
Harriet Feick, MD  
Stephen Crane, MD  
Sue Nicholas, CNP  
Julie Wright, BSN  
Melonee Michelson, MA  
Susan Howson, MSN  
Katrina Wolford  
Nancy Carst, MSW
Who Should Attend
This conference is designed for obstetricians, pediatric specialists, perinatal nurses and caregivers working with families with prenatally-diagnosed birth defects or patients who have undergone fetal intervention.

Continuing Education
Children’s Hospital Medical Center of Akron is accredited by the Ohio State Medical Association to provide continuing medical education for physicians. Children’s Hospital Medical Center of Akron designates this live educational activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Statement
As a provider of the Ohio State Medical Association, it is the policy to require the disclosure of the existence of any financial interest a planning committee member and presenters have with either the commercial supporter(s) of this activity or the manufacture(s) of any commercial product(s) discussed, and when necessary, resolve any potential conflict. None of the planning committee members or presenters has a financial conflict to disclose or resolve.

Registration
Registration deadline is Sept. 5, 2014.

Planning Committee
Melissa Mancuso, MD
Haynes B. Robinson, MD
Harriet Feick, MD
Stephen Crane, MD
Sue Nicholas, CNP
Julie Wright, BSN
Melonie Michelson, MA
Susan Howson, MSN
Katrina Wolford
Nancy Carst, MSW
Course Objectives

State of Fetal Treatment 2014
Timothy Crombleholme, MD
- Summarize available treatment models of management for prenatally-detected fetal anomalies including myelomeningocele, congenital diaphragmatic hernia, bladder outlet obstruction, twin-twin transfusion syndrome, cervical teratoma and others
- Describe data from research trials on emerging intervention strategies for birth defects
- Identify prenatal management strategies for pregnancies complicated by birth defects

State of Prenatal Diagnosis: Integration of Non-Invasive Screening and Prenatal Microarray into Fetal Medicine
Melissa Mancuso, MD
- Describe benefits and limitations of prenatal cell-free DNA screening in maternal blood
- Identify the efficacy and yield of prenatal chromosomal microarray analysis as compared with karyotyping for prenatal diagnosis when a fetal anomaly is identified

Congenital Heart Defects: Early Prenatal Detection and Treatment
Jack Rychik, MD
- Describe the progress in the prenatal diagnosis of congenital heart defects including early prenatal diagnosis
- Identify candidates and techniques utilized in fetal cardiac surgery
- Summarize data from research trials involving fetal cardiac intervention

Skeletal Dysplasias: Prenatal Diagnosis and Management
Deborah Krakow, MD
- Describe ultrasound techniques for prenatally diagnosing skeletal dysplasias
- Summarize advances in genetic testing for skeletal dysplasias
- Identify management strategies for prenatally identified skeletal disorders

The Future of Fetal Medicine: Gene/Stem Cell Therapy
Timothy Crombleholme, MD
- Describe new directions in non-invasive fetal therapy such as enzyme and gene therapy for a select group of genetic disorders
- Identify the diseases undergoing research trials for prenatal gene and stem cell therapy
- Summarize how new trends in non-invasive fetal therapies could change the field of fetal medicine

Point/Counterpoint: Fetal Surgery vs Postnatal Repair of Myelomeningocele and Complex Cardiac Defects
Jack Rychik, MD, Timothy Crombleholme, MD, Roger Hudgins, MD, Melissa Mancuso, MD, Philip Smith, MD
Moderator: Jeff St. Clair, WKSU
- Describe areas of ethical concern involved in service delivery for patients and their families experiencing birth defects
- Summarize counseling issues involved in evidence-based fetal therapies versus new experimental therapies currently in the research trial phase

Program Agenda

Friday, Sept. 19, 2014

8 - 9 a.m. State of Fetal Treatment 2014
Timothy Crombleholme, MD

9 – 9:15 a.m. Break

9:15 – 10:15 a.m. State of Prenatal Diagnosis: Integration of Non-Invasive Screening and Prenatal Microarray into Fetal Medicine
Melissa Mancuso, MD

10:15 – 11:30 a.m. Congenital Heart Defects: Early Prenatal Detection and Treatment Strategies
Jack Rychik, MD

11:30 a.m. – 12:30 p.m. Lunch

12:30 – 1:45 p.m. Skeletal Dysplasias: Prenatal Diagnosis and Management
Deborah Krakow, MD

1:45 – 2:45 p.m. The Future of Fetal Medicine: Gene/Stem Cell Therapy
Timothy Crombleholme, MD

2:45 – 2:55 p.m. Break

2:55 – 4:15 p.m. Point/Counterpoint: Fetal Surgery vs Postnatal Repair of Myelomeningocele and Complex Cardiac Defects
Moderator: NPR Personality Panelists: Tim Crombleholme, MD Roger Hudgins, MD, Melissa Mancuso, MD, Jack Rychik, MD, Philip Smith, MD
Moderator: Jeff St. Clair

Conference material will be distributed electronically.

Mail this form and payment to:
Akron Children’s Hospital
Attn: Katrina Wolford
One Perkins Square
Akron, OH 44308-1062

To register online, visit http://bit.ly/PrenatalConf

For more information, contact Melonie Michelson at 330-543-8684 or mmichelson@chmca.org.
Course Objectives

State of Fetal Treatment 2014
Timothy Crombleholme, MD
- Summarize available treatment models of management for prenatally-detected fetal anomalies including myelomeningocele, congenital diaphragmatic hernia, bladder outlet obstruction, twin-twin-transfusion syndrome, cervical teratoma and others
- Describe data from research trials on emerging intervention strategies for birth defects
- Identify prenatal management strategies for pregnancies complicated by birth defects

State of Prenatal Diagnosis: Integration of Non-Invasive Screening and Prenatal Microarray into Fetal Medicine
Melissa Mancuso, MD
- Describe benefits and limitations of prenatal cell free DNA screening in maternal blood
- Identify the efficacy and yield of prenatal chromosomal microarray analysis as compared with karyotyping for prenatal diagnosis when a fetal anomaly is identified

Congenital Heart Defects: Early Prenatal Detection and Treatment
Jack Rychik, MD
- Describe the progress in the prenatal diagnosis of congenital heart defects including early prenatal diagnosis
- Identify candidates and techniques utilized in fetal cardiac surgery
- Summarize data from research trials involving fetal cardiac intervention

Skeletal Dysplasias: Prenatal Diagnosis and Management
Deborah Krakow, MD
- Describe ultrasound techniques for prenatally diagnosing skeletal dysplasias
- Summarize advances in genetic testing for skeletal dysplasias
- Identify management strategies for prenatally identified skeletal disorders

The Future of Fetal Medicine: Gene/Stem Cell Therapy
Timothy Crombleholme, MD
- Describe new directions in non-invasive fetal therapy such as enzyme and gene therapy for a select group of genetic disorders
- Identify the diseases undergoing research trials for prenatal gene and stem cell therapy
- Summarize how new trends in non-invasive fetal therapies could change the field of fetal medicine

Point/Counterpoint: Fetal Surgery vs Postnatal Repair of Myelomeningocele and Complex Cardiac Defects
Jack Rychik, MD, Timothy Crombleholme, MD, Roger Hugdins, MD, Melissa Mancuso, MD
- Discuss areas of ethical concern involved in service delivery for patients and their families experiencing birth defects
- Summarize counseling issues involved in evidence-based fetal therapies vs new experimental therapies currently in the research trial phase

Program Agenda

Friday, Sept. 19, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 - 9 a.m.</td>
<td>State of Fetal Treatment 2014</td>
<td>Timothy Crombleholme, MD</td>
</tr>
<tr>
<td>9 – 9:15 a.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>9:15 – 10:15 a.m.</td>
<td>State of Prenatal Diagnosis: Integration of Non-Invasive Screening</td>
<td>Melissa Mancuso, MD</td>
</tr>
<tr>
<td>10:15 – 11:30 a.m.</td>
<td>Congenital Heart Defects: Early Prenatal Detection and Treatment</td>
<td>Jack Rychik, MD</td>
</tr>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:30 – 1:45 p.m.</td>
<td>Skeletal Dysplasias: Prenatal Diagnosis and Management</td>
<td>Deborah Krakow, MD</td>
</tr>
<tr>
<td>1:45 – 2:45 p.m.</td>
<td>The Future of Fetal Medicine: Gene/Stem Cell Therapy</td>
<td>Timothy Crombleholme, MD</td>
</tr>
<tr>
<td>2:45 – 2:55 p.m.</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
| 2:55 – 4:15 p.m. | Point/Counterpoint: Fetal Surgery vs Postnatal Repair of Myelomeningocele and Complex Cardiac Defects | Roger Hugdins, MD, Melissa Mancuso, MD, Jack Rychik, MD, Philip Smith, MD | Moderator: Jeff St. Clair
Course Objectives

State of Fetal Treatment 2014
Timothy Crombleholme, MD
- Summarize available treatment models of management for prenatally-detected fetal anomalies including myelomeningocele, congenital diaphragmatic hernia, bladder outlet obstruction, twin-twin-transfusion syndrome, cervical teratoma and others
- Describe data from research trials on emerging intervention strategies for birth defects
- Identify prenatal management strategies for pregnancies complicated by birth defects

State of Prenatal Diagnosis: Integration of Non-Invasive Screening and Prenatal Microarray into Fetal Medicine
Melissa Mancuso, MD
- Describe benefits and limitations of prenatal cell free DNA screening in maternal blood
- Identify the efficacy and yield of prenatal chromosomal microarray analysis as compared with karyotyping for prenatal diagnosis when a fetal anomaly is identified

Congenital Heart Defects: Early Prenatal Detection and Treatment
Jack Rychik, MD
- Describe the progress in the prenatal diagnosis of congenital heart defects including early prenatal diagnosis
- Identify candidates and techniques utilized in fetal cardiac surgery
- Summarize data from research trials involving fetal cardiac intervention

Skeletal Dysplasias: Prenatal Diagnosis and Management
Deborah Krakow, MD
- Describe ultrasound techniques for prenatally diagnosing skeletal dysplasias
- Summarize advances in genetic testing for skeletal dysplasias
- Identify management strategies for prenatally identified skeletal disorders

The Future of Fetal Medicine: Gene/Stem Cell Therapy
Timothy Crombleholme, MD
- Describe new directions in non-invasive fetal therapy such as enzyme and gene therapy for a select group of genetic disorders
- Identify the diseases undergoing research trials for prenatal gene and stem cell therapy
- Summarize how new trends in non-invasive fetal therapies could change the field of fetal medicine

Point/Counterpoint: Fetal Surgery vs Postnatal Repair of Myelomeningocele and Complex Cardiac Defects
Jack Rychik, MD, Timothy Crombleholme, MD, Roger Hudgins, MD, Melissa Mancuso, MD, Phillip Smith, MD
Moderator: Jeff St. Clair, WKSU
- Describe areas of ethical concern involved in service delivery for patients and their families experiencing birth defects
- Summarize counseling issues involved in evidence-based fetal therapies vs new experimental therapies currently in the research trial phase

Program Agenda

Friday, Sept. 19, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 - 9 a.m.</td>
<td>State of Fetal Treatment 2014</td>
<td>Timothy Crombleholme, MD</td>
</tr>
<tr>
<td>9 – 9:15 a.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>9:15 – 10:15 a.m.</td>
<td>State of Prenatal Diagnosis: Integration of Non-Invasive Screening and Prenatal Microarray into Fetal Medicine</td>
<td>Melissa Mancuso, MD</td>
</tr>
<tr>
<td>10:15 – 11:30 a.m.</td>
<td>Congenital Heart Defects: Early Prenatal Detection and Treatment Strategies</td>
<td>Jack Rychik, MD</td>
</tr>
<tr>
<td>11:30 a.m. – 12:30 p.m.</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:30 – 1:45 p.m.</td>
<td>Skeletal Dysplasias: Prenatal Diagnosis and Management</td>
<td>Deborah Krakow, MD</td>
</tr>
<tr>
<td>1:45 – 2:45 p.m.</td>
<td>The Future of Fetal Medicine: Gene/Stem Cell Therapy</td>
<td>Timothy Crombleholme, MD</td>
</tr>
<tr>
<td>2:45 – 2:55 p.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:55 – 4:15 p.m.</td>
<td>Point/Counterpoint: Fetal Surgery vs Postnatal Repair of Myelomeningocele and Complex Cardiac Defects</td>
<td>Moderator: NPR Personality Panelists: Tim Crombleholme, MD, Roger Hudgins, MD, Melissa Mancuso, MD, Jack Rychik, MD, Phillip Smith, MD, Moderator: Jeff St. Clair</td>
</tr>
</tbody>
</table>

Conference material will be distributed electronically.

Mail this form and payment to:
Akron Children’s Hospital
Attn: Katrina Wolfdolf
One Perkins Square
Akron, OH 44308-1062

Registration deadline is Sept. 5, 2014
For more information, contact Melonie Michelson at 330-543-8684 or mmichelson@chmca.org.
Who Should Attend
This conference is designed for obstetricians, pediatric specialists, perinatal nurses and caregivers working with families with prenatally-diagnosed birth defects or patients who have undergone fetal intervention.

Continuing Education
Children's Hospital Medical Center of Akron is accredited by the Ohio State Medical Association to provide continuing medical education for physicians. Children's Hospital Medical Center of Akron designates this live educational activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Statement
As a provider of the Ohio State Medical Association, it is the policy to require the disclosure of the existence of any financial interest a planning committee member and presenters have with either the commercial supporter(s) of this activity or the manufacturer(s) of any commercial product(s) discussed, and when necessary, resolve any potential conflict. None of the planning committee members or presenters has a financial conflict to disclose or resolve.

Registration
Registration deadline is Sept. 5, 2014.
Course Objectives

State of Fetal Treatment 2014
Timothy Crombleholme, MD
- Summarize available treatment models of management for prenatally-detected fetal anomalies including myelomeningocele, congenital diaphragmatic hernia, bladder outlet obstruction, twin-twin transfusion syndrome, cervical teratoma and others
- Describe data from research trials on emerging intervention strategies for birth defects
- Identify prenatal management strategies for pregnancies complicated by birth defects

State of Prenatal Diagnosis: Integration of Non-Invasive Screening and Prenatal Microarray into Fetal Medicine
Melissa Mancuso, MD
- Describe benefits and limitations of prenatal cell free DNA screening in maternal blood
- Identify the efficacy and yield of prenatal chromosomal microarray analysis as compared with karyotyping for prenatal diagnosis when a fetal anomaly is identified

Congenital Heart Defects: Early Prenatal Detection and Treatment
Jack Rychik, MD
- Describe the progress in the prenatal diagnosis of congenital heart defects including early prenatal diagnosis
- Identify candidates and techniques utilized in fetal cardiac surgery
- Summarize data from research trials involving fetal cardiac intervention

Skeletal Dysplasias: Prenatal Diagnosis and Management
Deborah Krakow, MD
- Describe ultrasound techniques for prenatally diagnosing skeletal dysplasias
- Summarize advances in genetic testing for skeletal dysplasias
- Identify management strategies for prenatally identified skeletal disorders

The Future of Fetal Medicine: Gene/Stem Cell Therapy
Timothy Crombleholme, MD
- Describe new directions in non-invasive fetal therapy such as enzyme and gene therapy for a select group of genetic disorders
- Identify the diseases undergoing research trials for prenatal gene and stem cell therapy
- Summarize how new trends in non-invasive fetal therapies could change the field of fetal medicine

Point/Counterpoint: Fetal Surgery vs Postnatal Repair of Myelomeningocele and Complex Cardiac Defects
Jack Rychik, MD, Timothy Crombleholme, MD, Roger Hudgins, MD, Melissa Mancuso, MD, Phillip Smith, MD
Moderator: Jeff St. Clair, WKSU
- Describe areas of ethical concern involved in service delivery for patients and their families experiencing birth defects
- Summarize counseling issues involved in evidence-based fetal therapies vs new experimental therapies currently in the research trial phase

Conference material will be distributed electronically.

To register online, visit http://bit.ly/PrenatalConf

Akron Children’s Hospital offers several registration and payment options. You may go online and register and pay electronically, or you may register online and pay by check. Alternatively, you may complete the form below and pay by check.

To register online, visit http://bit.ly/PrenatalConf

Mail this form and payment to:
Akron Children’s Hospital
Attention: Katrina Wolford
One Perkins Square
Akron, OH 44308-1062

Registration deadline is Sept. 5, 2014
For more information, contact Melonie Michelson at 330-543-8684 or mmichelson@chmca.org.
Who Should Attend
This conference is designed for obstetricians, pediatric specialists, perinatal nurses and caregivers working with families with prenatally-diagnosed birth defects or patients who have undergone fetal intervention.

Continuing Education
Children’s Hospital Medical Center of Akron is accredited by the Ohio State Medical Association to provide continuing medical education for physicians. Children’s Hospital Medical Center of Akron designates this live educational activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Statement
As a provider of the Ohio State Medical Association, it is the policy to require the disclosure of the existence of any financial interest a planning committee member and presenters have with either the commercial supporter(s) of this activity or the manufacture(s) of any commercial product(s) discussed, and when necessary, resolve any potential conflict. None of the planning committee members or presenters has a financial conflict to disclosure or resolve.

Registration
Registration deadline is Sept. 5, 2014.

Planning Committee
Melissa Mancuso, MD
Haynes B. Robinson, MD
Harriet Feick, MD
Stephen Crane, MD
Sue Nicholas, CNP
Julie Wright, BSN
Melonie Michelson, MA
Susan Howson, MSN
Katrina Wolford
Nancy Carst, MSW